| PDE5A |
| LOCUS ID | 8654 | |||||||||||||
| GENE_SYMBOL | PDE5A | |||||||||||||
| GENE NAME | phosphodiesterase 5A | |||||||||||||
| SYNONYMNS | CN5A, PDE5, CGB-PDE | |||||||||||||
| CHROMOSOME | 4 | |||||||||||||
| HOMOLOGENE ID | 842 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| This gene encodes a cGMP-binding, cGMP-specific phosphodiesterase, a member of the cyclic nucleotide phosphodiesterase family. This phosphodiesterase specifically hydrolyzes cGMP to 5'-GMP. It is involved in the regulation of intracellular concentrations of cyclic nucleotides and is important for smooth muscle relaxation in the cardiovascular system. Alternative splicing of this gene results in three transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008] |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. PDE 5 inhibitors may have, therefore, the potential to reduce glomerular hypertension. 2. This review describes the use of PDE 5 inhibitors to improve the metabolic haemodynamic and inflammatory pathway responses | 23961322 |
| Neuropathy | 1. These data indicate that hyperglycemia substantially upregulates PDE5 expression and that the cGMP/PKG signaling pathway activated by sildenafil mediates the beneficial effects of sildenafil on diabetic peripheral neuropathy. | 21820491 |